Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Common Equity: 2012-2025

Historic Common Equity for CorMedix (CRMD) over the last 11 years, with Sep 2025 value amounting to $374.1 million.

  • CorMedix's Common Equity rose 537.23% to $374.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $374.1 million, marking a year-over-year increase of 537.23%. This contributed to the annual value of $84.7 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, CorMedix's Common Equity is $374.1 million, which was up 69.57% from $220.6 million recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Common Equity peaked at $374.1 million during Q3 2025, and registered a low of $46.2 million during Q2 2024.
  • For the 3-year period, CorMedix's Common Equity averaged around $114.3 million, with its median value being $71.0 million (2023).
  • In the last 5 years, CorMedix's Common Equity decreased by 29.43% in 2024 and then spiked by 537.23% in 2025.
  • CorMedix's Common Equity (Quarterly) stood at $62.8 million in 2021, then decreased by 12.32% to $55.1 million in 2022, then skyrocketed by 47.75% to $83.2 million in 2023, then dropped by 29.43% to $84.7 million in 2024, then surged by 537.23% to $374.1 million in 2025.
  • Its Common Equity was $374.1 million in Q3 2025, compared to $220.6 million in Q2 2025 and $114.9 million in Q1 2025.